Affiliations: Mécanique et Ingénierie Cellulaire et Tissulaire, UMR CNRS 7563 LEMTA et IFR 111, Faculté de Médecine, Vandoeuvre-lès-Nancy, France | Departement de Chirurgie Orthopédique, CHU Nancy, France
Note: [] Address for correspondence: Natalia G. de Isla, Groupe d'Ingénierie Cellulaire et Tissulaire, UMR CNRS 7563 and IFR 111 Bioingenierie, BP 184, Faculté de Médecine, UHP-Nancy I, 54500 Vandoeuvre-lès-Nancy, France. Tel.: +33 383 683457; Fax: +33 383 683459; E-mail: ndeisla@medecine.uhp-nancy.fr.
Abstract: Osteoarthritis (OA) is a progressive joint disease which represents a combination of several disorders leading to cartilage degradation. The production of nitric oxide (NO) by iNOS, which is stimulated by proinflammatory mediators, is involved in cartilage catabolism and should therefore be considered a potential target for therapeutic interventions. Diacerein is a slow-acting drug that may slow down the breakdown of cartilage and relieve pain and swelling. Diacerhein, in contrast to an NSAID, is a potent inhibitor of IL-1β induced NO production by chondrocytes and cartilage. This effect appeared to result from iNOS transcriptional and/or post-transcriptional events, maybe by the inhibition of the NF-κB transcription factor. This paper presents results on the influence of Diacerein on NO production.
Keywords: Articular chondrocytes, diacerein, nitric oxide, NO synthase
